Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa

Clinical Endocrinology

Volumn 67, Issue 2, 2007, Pages 282-289

  Maiza, Jean Christophe ^a   Vezzosi, Delphine ^a   Matta, Maria ^a   Donadille, Florence ^a   Loubes Lacroix, Florence ^a   Cournot, Maxime ^b   Bennet, Antoine ^a   Caron, Philippe ^a  

^a CHU RANGUEIL   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; BROMOCRIPTINE; BROMOCRIPTINE MESILATE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; OCTREOTIDE; QUINAGOLIDE; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADENOMA; ADOLESCENT; ADULT; AGED; ARTICLE; CHOLELITHIASIS; CLINICAL ARTICLE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMPTY SELLA SYNDROME; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; GONADOTROPHIN INSUFFICIENCY; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE SECRETING ADENOMA; HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; HYPOPHYSIS FUNCTION; HYPOPITUITARISM; INJECTION SITE INDURATION; MACROADENOMA; MALE; MICROADENOMA; PATIENT MONITORING; PRIORITY JOURNAL; SIDE EFFECT; THYROTROPHIN INSUFFICIENCY; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; CHI-SQUARE DISTRIBUTION; DOPAMINE AGONISTS; FEMALE; FOLLOW-UP STUDIES; GROWTH HORMONE; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OCTREOTIDE; PEPTIDES, CYCLIC; PITUITARY NEOPLASMS; PROSPECTIVE STUDIES; SOMATOSTATIN; STATISTICS, NONPARAMETRIC; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 34447513998     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2007.02878.x     Document Type: Article

References (40)

1. Colao, A., Ferone, D., Marzullo, P. Lombardi, G. (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocrine Reviews, 25, 102 152.
2. Holdaway, I.M., Rajasoorya, R.C. Gamble, G.D. (2004) Factors influencing mortality in acromegaly. Journal of Clinical Endocrinology and Metabolism, 89, 667 674.
3. Biermasz, N.R., Van Dulken, H. Roelfsema, F. (2000) Ten-year follow-up results of transsphenoidal microsurgery in acromegaly. Journal of Clinical Endocrinology and Metabolism, 85, 4596 4602.
4. Kreutzer, J., Vance, M.L., Lopes, M.B.S. Laws, E.R. (2001) Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. Journal of Clinical Endocrinology and Metabolism, 86, 4072 4077.
5. Barker, F.G., Klibanski, A. Swearingen, B. (2003) Transsphenoidal surgery for pituitary tumors in the United States, 1996-2000: mortality, morbidity, and the effects of hospital and surgeon volume. Journal of Clinical Endocrinology and Metabolism, 88, 4709 4719.
6. Nomikos, P., Buchfelder, M. Fahlbusch, R. (2005) The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical cure. European Journal of Endocrinology, 152, 379 387.
7. Barrande, G., Pittino-Lungo, M., Coste, J., Ponvert, D., Bertagna, X., Luton, J.P. Bertherat, J. (2000) Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center. Journal of Clinical Endocrinology and Metabolism, 85, 3779 3785.
8. Attanassio, R., Epaminonda, P., Motti, E., Guigni, E., Ventrella, L., Cozzi, R., Farabola, M., Loli, P., Beck-Peccoz, P. Arosio, M. (2003) Gamma-knife radiosurgery in acromegaly: a 4-year follow-up study. Journal of Clinical Endocrinology and Metabolism, 88, 3105 3112.
9. Castinetti, F., Taieb, D., Khun, J.M., Chanson, P., Tamura, M., Jacquet, P., Conte-Devolx, B., Regis, J., Dufour, H. Brue, T. (2005) Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion. Journal of Clinical Endocrinology and Metabolism, 90, 4483 4488.
10. Davies, P.H., Stewart, S.E., Lancranja, I., Scheppard, M.C. Stewart, P.M. (1998) Long-term therapy with long-acting octreotide (Sandostatin-LAR®) for the management of acromegaly. Clinical Endocrinology, 48, 311 316.
11. Caron, P., Beckers, A., Cullen, D.R., Goth, M.I., Gutt, B., Laurberg, P., Pico, A.M., Valimaki, M. Zgliczynski, W. (2002) Efficacy of the new long-acting formulation of lanreotide (lanreotide autogel) in the management of acromegaly. Journal of Clinical Endocrinology and Metabolism, 87, 99 104.
12. Attanasio, R., Baldelli, R., Pivonello, R., Grottoli, S., Bocca, L., Gasco, V., Giusti, M., Tamburrano, G., Colao, A. Cozzi, R. (2003) Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly. Journal of Clinical Endocrinology and Metabolism, 88, 5258 5265.
13. Abstract, R., Verhelst, J., Maiter, D., Van Acker, K., Nobels, F., Coolens, J.L., Mahler, C. Beckers, A. (1998) Cabergoline in the treatment of acromegaly: a study in 64 patients. Journal of Clinical Endocrinology and Metabolism, 83, 374 378.
14. Paisley, A.N., Trainer, P.J. Drake, W.M. (2004) The place of pegvisomant in the acromegaly treatment algorithm. Growth Hormone and IGF Research, 14, 101 106.
15. Di Chiro, G. Nelson, K.B. (1962) The volume of the sella turcica. American Journal of Radiology, 87, 989 1008.
16. Lundin, P., Engstöm, B.E., Karlsson, F.A. Burman, P. (1997) Long-term octreotide therapy in growth hormone-secreting pituitary adenomas: evaluation with serial MR. American Journal of Neuroradiology, 18, 765 772.
17. Baldelli, R., Colao, A., Razzore, P., Jaffrain-Rea, M.L., Marzullo, P., Ciccarelli, E., Ferretti, E., Ferone, D., Gaia, D., Camanni, F., Lombardi, G. Tamburrano, G. (2000) Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg). Journal of Clinical Endocrinology and Metabolism, 85, 4099 4103.
18. Colao, A., Ferone, D., Marzullo, P., Cappabianca, P., Cirillo, S., Boerlin, V., Ioana, L. Lombardi, G. (2001) Long-term effects of depot long-acting somatostatin analog octrotid on hormone levels and tumor mass in acromegaly. Journal of Clinical Endocrinology and Metabolism, 86, 2779 2786.
19. Ayuk, J., Stewart, S.E., Stewart, P.M. Sheppard, M.C. (2002) Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly. Journal of Clinical Endocrinology and Metabolism, 87, 4142 4146.
20. Bevan, J.S., Atkin, S.L., Atkinson, A.B., Bouloux, P.M., Hanna, F., Harris, P.E., James, R.A., McConnell, M., Roberts, G.A., Scanlon, M.F., Stewart, P.M., Teasdale, E., Turner, H.E., Wass, J.A.H. Wardlaw, J.M. (2002) Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. Journal of Clinical Endocrinology and Metabolism, 87, 4554 4563.
21. Amato, G., Mazziotti, G., Rotondi, M., Iorio, S., Doga, M., Sorvillo, F., Manganella, G., Di Salle, F., Giustina, A. Carella, C. (2002) Long-term effects of lanreotide SR and octreotide LAR® on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clinical Endocrinology, 56, 65 71.
22. Cozzi, R., Attanasio, R., Montini, M., Pagani, G., Lasio, G., Lodrini, S., Barausse, M., Albizzi, M., Dallabonzana, D. Pedroncelli, A. (2003) Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? Journal of Clinical Endocrinology and Metabolism, 88, 3090 3098.
23. Cozzi, R., Montini, M., Attanasio, R., Albizzi, M., Lasio, G., Lodrini, S., Doneda, P., Cortesi, L. Pagani, G. (2006) Primary treatment of acromegaly with octreotide LAR: a long term (up to 9 years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. Journal of Clinical Endocrinology and Metabolism, 91, 1397 1403.
24. Melmed, S., Sternberg, R., Cook, D., Klibanski, A., Chanson, P., Bonert, V., Vance, M.L., Rhew, D., Kleinberg, D. Barkan, A. (2005) A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. Journal of Clinical Endocrinology and Metabolism, 90, 4405 4410.
25. Freda, P.U., Katznelson, L., van der Lely, A.J., Reyes, C.M., Zhao, S. Rabinowitz, D. (2005) Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. Journal of Clinical Endocrinology and Metabolism, 90, 4465 4473.
26. Colao, A., Attanasio, R., Pivonello, R., Cappabianca, P., Cavallo, L.M., Lasio, G., Lodrini, A., Lombardi, G. Cozzi, R. (2005) Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. Journal of Clinical Endocrinology and Metabolism, 91, 85 92.
27. Petrossians, P., Borges-Martins, L., Espinoza, C., Daly, A., Betea, D., Valdes-Socin, H., Stevenaert, A., Chanson, P. Beckers, A. (2005) Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. European Journal of Endocrinology, 152, 61 66.
28. Cozzi, R., Attanasio, R., Lodrini, S. Lasio, G. (2004) Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clinical Endocrinology, 61, 209 215.
29. Jaquet, P., Saveanu, A., Dufour, H., Taylor, J., Dong, J., Kim, S., Moreau, J.P., Enjalbert, A. Culler, M.D. (2005) Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. European Journal of Endocrinology, 153, 135 141.
30. Ren, S.G., Kim, S., Taylor, J., Dong, J., Moreau, J.P., Culler, M.D. Melmed, S. (2003) Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand. Journal of Clinical Endocrinology and Metabolism, 88, 5414 5421.
31. Selvarajah, D., Webster, J., Ross, R. Newell-Price, J. (2005) Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. European Journal of Endocrinology, 152, 569 574.
32. Feenstra, J., de Herder, W.W., ten Have, S.M., van den Beld, A.W., Feelders, M.D., Janssen, J.A. van der Lely, A.J. (2005) Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet, 365, 1644 1646.
33. Jorgensen, J., Feldt-Rasmussen, U., Frystyk, J., Chen, J., Kristensen, L., Hagen, C. Orskov, H. (2005) Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. Journal of Clinical Endocrinology and Metabolism, 90, 5627 5631.
34. Bevan, J.S. (2005) The antitumoral effects of somatostatin analog therapy in acromegaly. Journal of Clinical Endocrinology and Metabolism, 90, 1856 1863.
35. Hayashi, S., Takano, K., Yasufuku-Takano, J., Fujita, T. Teramoto, A. (2005) Mechanisms of octreotide-induced tumor shrinkage of GH-secreting adenoma. European Journal of Endocrinology, 152 (Suppl. 1 501.
36. Ezzat, S., Horvath, E., Harris, A.G. Kovacs, K. (1994) Morphological effects of octreotide on growth hormone-producing pituitary adenomas. Journal of Clinical Endocrinology and Metabolism, 79, 113 118.
37. Tomlinson, J.W., Holden, N., Hills, R.K., Wheatley, K., Clayton, R.N., Bats, A.S., Sheppard, M.C. Stewart, P.M. (2001) Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet, 357, 425 431.
38. Gittoes, N.J.L. (2005) Pituitary radiotherapy: current controversies. Trends in Endocrinology and Metabolism, 16, 407 413.
39. Caron, P., Cogne, M., Raingeard, I., Bex-Bachellerie, V. Kuhn, J.M. (2006) Effectiveness and tolerability of 3-year lanreotide Autogel® treatment in patients with acromegaly. Clinical Endocrinology, 1, 209 214.
40. Melmed, S., Casanueva, F.F., Cavagnini, F., Chanson, P., Frohman, L., Grosman, A., Ho, K., Kleinberg, D., Lamberts, S., Laws, E., Lombardi, G., Vance, M.L., Von Werder, K., Wass, J. Giustina, A. (2002) Consensus guidelines for acromegaly management. Journal of Clinical Endocrinology and Metabolism, 87, 4054 4058.